The possibility to administer the NAX014 agent through oral method, with an extended activity over the primary tumor to the lung metastases in comparison with the intraperitoneal method, considerably improves its relevance as new potential therapeutic tool in the treatment of HER-2 positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.